Form 4: Apellis Pharmaceuticals Executive Karen Lewis Reports Stock Sale and RSU Award

Karen Lewis, Chief People Officer of Apellis Pharmaceuticals, reports selling shares to cover tax withholding and receiving a restricted stock unit (RSU) award.

Summary

• Karen Lewis, Chief People Officer of Apellis Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On January 17, 2025, Lewis sold 1,241 shares of common stock at a price of $29.9582 per share to cover tax withholding related to released Restricted Stock Units.
• Following this transaction, Lewis directly owned 43,858 shares of Apellis Pharmaceuticals common stock.
• On January 21, 2025, Lewis was granted a Restricted Stock Unit (RSU) award for 28,508 shares.
• The RSU award vests 25% annually over four years from the grant date, contingent upon continued service.
• After the RSU award, Lewis's direct ownership increased to 72,366 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine transactions (stock sale for tax purposes and RSU grant) and doesn't inherently indicate positive or negative news about the company's performance.

Positives

• The granting of RSUs to a key executive suggests the company is incentivizing long-term performance and retention.

Negatives

• The sale of shares by an executive, even for tax purposes, could be perceived negatively by some investors, although it's a common practice.

Risks

• Executive stock sales, even for tax obligations, can sometimes signal a lack of confidence, although this is likely not the case here.
• The vesting of RSUs is contingent on continued service, creating a potential risk if the executive were to leave the company before full vesting.

Future Outlook

The RSU award vests over four years, indicating a commitment to the company's future.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders. RSU grants are a common form of executive compensation in the pharmaceutical industry.

Comparison to Industry Standards

• RSU grants are a typical component of executive compensation packages in the pharmaceutical industry, aligning executive interests with shareholder value.
• Companies like Regeneron, Vertex, and Biogen also utilize RSU grants as part of their executive compensation strategy.
• The vesting schedule of 25% annually over four years is a standard vesting schedule seen across the industry.

Stakeholder Impact

• Shareholders are informed about executive stock transactions, promoting transparency.
• Employees may view RSU grants to executives as a positive sign of company investment in its leadership.

Key Dates